John is SVP, Immune Oncology and Head of Bispecifics at Regeneron, where he works on bispecific antibodies and other novel biologics platforms across all therapeutic areas, including oncology, autoimmunity, allergy, transplant, infectious diseases, metabolic diseases and ophthalmology.
 John’s career is focused on developing novel biologics to address the pathogenic mechanisms of important human diseases across many therapeutic areas. Previously, he had worked at a biotech startup, Rinat Neuroscience Inc. (which was a Genentech spin-off), since its inception in 2002 and continuing through its acquisition by Pfizer in 2006. Before that I was a postdoctoral fellow at Genentech Inc. from 1999-2001. I completed my Ph.D. in Biological and Biomedical Sciences from Harvard University in 1998, and M.D. from the College of Medicine of National Taiwan University in 1992.